233 related articles for article (PubMed ID: 21663505)
1. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
Warlick ED; Miller JS
Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?
Braun T; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):327-36. PubMed ID: 24507810
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
5. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
Front Immunol; 2021; 12():665541. PubMed ID: 33986753
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
[TBL] [Abstract][Full Text] [Related]
8. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
[TBL] [Abstract][Full Text] [Related]
9. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
Sarhan D; Brandt L; Felices M; Guldevall K; Lenvik T; Hinderlie P; Curtsinger J; Warlick E; Spellman SR; Blazar BR; Weisdorf DJ; Cooley S; Vallera DA; Önfelt B; Miller JS
Blood Adv; 2018 Jun; 2(12):1459-1469. PubMed ID: 29941459
[TBL] [Abstract][Full Text] [Related]
10. Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes.
Banerjee T; Calvi LM; Becker MW; Liesveld JL
Blood Rev; 2019 Jul; 36():57-69. PubMed ID: 31036385
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
12. [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome].
Mi H; Fu R; Wang H; Qu W; Ruan E; Wang X; Wang G; Liu H; Wu Y; Song J; Xing L; Guan J; Li L; Jiang H; Zhang W; Yue L; Shao Z
Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):737-41. PubMed ID: 24844955
[TBL] [Abstract][Full Text] [Related]
13. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
[TBL] [Abstract][Full Text] [Related]
14. Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
Ivy KS; Brent Ferrell P
Curr Hematol Malig Rep; 2018 Aug; 13(4):244-255. PubMed ID: 29934935
[TBL] [Abstract][Full Text] [Related]
15. [The research update on cellular immune abnormality in myelodysplastic syndrome--review].
Xu F; Liu T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):673-7. PubMed ID: 14706159
[TBL] [Abstract][Full Text] [Related]
16. The role of the immune system in myelodysplasia: implications for therapy.
Sloand EM; Rezvani K
Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
[TBL] [Abstract][Full Text] [Related]
17. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
Stankov K; Stankov S; Katanic J
Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
[TBL] [Abstract][Full Text] [Related]
18. Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.
Montes P; Bernal M; Campo LN; González-Ramírez AR; Jiménez P; Garrido P; Jurado M; Garrido F; Ruiz-Cabello F; Hernández F
Cancer Immunol Immunother; 2019 Dec; 68(12):2015-2027. PubMed ID: 31705171
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
Ogata K; Yokose N; Nomura T
Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
[TBL] [Abstract][Full Text] [Related]
20. Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
Hua Y; Wang C; Jiang H; Wang Y; Liu C; Li L; Liu H; Shao Z; Fu R
Int J Hematol; 2017 Aug; 106(2):248-257. PubMed ID: 28405919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
